Use of Presepsin as a Marker for Immunotherapy Administration in Pneumonia
Status:
Recruiting
Trial end date:
2024-03-06
Target enrollment:
Participant gender:
Summary
The current study is an exploratory, phase IIa randomized clinical trial (RCT) aiming to
evaluate if early presepsin increase coupled with early initiation of anakinra as an adjunct
therapy to the standard-of-care treatment may improve outcomes of community-acquired
pneumonia or hospital-acquired pneumonia.